These authors observed that animals treated with TPPU presented a reduction in inflammation, atrial fibrosis, and electrical remodeling in atrial myocytes, suggesting sEH inhibition as a therapeutic target for the treatment of AF [117]. The gene discussed is EPHX2; the disease is atrial fibrillation.